Nasal allergies (or hay fever, pollen allergies, dust allergies, etc.) are medically known as "allergic rhinitis". The Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines were initiated during a World Health Organization workshop in 1999.
Per the ARIA guidelines 2018 update, intranasal corticosteroids are recommended as the primary treatment for patients with moderate-to-severe and/or persistent allergic rhinitis due to their efficacy in controlling nasal symptoms. Antihistamines can be taken orally or intranasally if preferred or if insufficient control is achieved with intranasal corticosteroids.
First-line recommendations:
Fluticasone: Intranasal corticosteroid spray, as needed or 2 sprays in each nostril per day. Dose: 0.05% (50 mcg/spray). Buy Fluticasone 0.05% 50mcg (FDA NDA 205434).
Second-line recommendations:
Azelestine: Intranasal antihistamine spray, as needed or 2 sprays in each nostril per day. Dose: 0.1% (137 mcg/spray). Buy azelestine 0.1% 137 mcg (FDA NDA 213872).
Loratidine: Second-generation oral antihistamine. Dose: Adults and children ≥ 6 years: loratadine 10 mg orally once daily. Buy loratadine 10 mg (FDA NDA 19658/S-020).
Prescription medications:
Decongestants and more advanced immunomodulatory medications such as leukotriene receptor antagonists may be prescribed for severe cases.
Citations:
Bousquet, J., Schünemann, H. J., Togias, A., et al. (2020). Next-generation Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines. Allergy, 75(8), 2041-2052.
